Corbus Pharmaceuticals (CRBP) CMO awarded RSUs and stock options in 2026 grant

Rhea-AI Filing Summary

Corbus Pharmaceuticals Holdings, Inc.'s Chief Medical Officer, Dominic Smethurst, reported equity awards received on January 14, 2026. He was granted 28,365 restricted stock units (RSUs) that will settle in common shares, with 25% vesting on each of the first four anniversaries beginning January 14, 2027, and a pro rata acceleration feature if his service is terminated by the company without cause after the first vesting date. He also received an annual stock option award for 85,095 shares at an exercise price of $8.26 per share, vesting 25% on January 14, 2027 and the remaining 75% in equal monthly installments over 36 months starting February 14, 2027. Following these transactions, he beneficially owned 99,172 shares of common stock, including 93,065 unvested RSUs subject to their existing vesting schedules.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Smethurst Dominic

(Last) (First) (Middle)

C/O CORBUS PHARMACEUTICALS HOLDINGS, INC

500 RIVER RIDGE DRIVE

(Street)

NORWOOD MA 02062

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Corbus Pharmaceuticals Holdings, Inc. [ CRBP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/14/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock, par value $0.0001 per share	01/14/2026		A		28,365(1)	A	$0	99,172(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock options (right to buy)	$8.26	01/14/2026		A		85,095		(3)	01/14/2036	Common Stock	85,095	$0	85,095	D

Explanation of Responses:

1. On January 14, 2026, the Reporting Person was granted 28,365 restricted stock units ("RSUs"), which will be settled in shares of common stock, par value $0.0001. 25% of the RSUs shall vest on each of the first, second, third and fourth anniversary beginning on January 14, 2027. Notwithstanding the foregoing, upon termination of the Reporting Person's Service by the Company without cause, provided that such termination occurs after the first Vesting Date, then a pro rata portion of the RSUs shall accelerate in an amount equal to the product of (x) the number of RSUs scheduled to vest on the next Vesting Date and (y) a fraction, the numerator of which is the number of completed months of service the Awardee worked since the most recent Vesting Date through the date of Awardees termination of Service and the denominator of which is 12. The RSUs, to the extent not accelerated in accordance with this paragraph shall be forfeited upon such Reporting Person's termination of service.

2. This amount includes 93,065 unvested RSUs subject to each grant's vesting schedule as previously reported.

3. The annual option award was made in accordance with the terms of the issuer's 2024 Equity Compensation Plan. 25% of the option vests on January 14, 2027, with the remaining 75% of the option vesting in equal monthly installments over a period of 36 months commencing on February 14, 2027.

	/s/ Meghan Houghton, Attorney-in-Fact for Dominic Smethurst	01/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider activity did CRBP's Chief Medical Officer report?

Corbus Pharmaceuticals Holdings, Inc.'s Chief Medical Officer, Dominic Smethurst, reported receiving grants of restricted stock units (RSUs) and stock options on January 14, 2026, rather than selling shares.

How many RSUs were granted to Dominic Smethurst in this Form 4 for CRBP?

Dominic Smethurst was granted 28,365 RSUs, which will be settled in shares of Corbus Pharmaceuticals Holdings, Inc. common stock, with 25% vesting each year on the first four anniversaries beginning January 14, 2027.

What stock option award was disclosed for CRBP's Chief Medical Officer?

The filing shows an annual stock option grant for 85,095 shares of Corbus Pharmaceuticals Holdings, Inc. common stock at an exercise price of $8.26 per share, vesting 25% on January 14, 2027 and the remaining 75% in equal monthly installments over 36 months starting February 14, 2027.

What is Dominic Smethurst's total reported CRBP share ownership after these grants?

After the reported transactions, Dominic Smethurst beneficially owned 99,172 shares of Corbus Pharmaceuticals Holdings, Inc. common stock, which includes 93,065 unvested RSUs that remain subject to their vesting schedules.

Is there any acceleration feature in the RSU grant for CRBP's Chief Medical Officer?

Yes. If Corbus Pharmaceuticals terminates Dominic Smethurst's service without cause after the first vesting date, a pro rata portion of the RSUs scheduled to vest on the next vesting date will accelerate based on completed months of service, with any remaining unvested RSUs forfeited.

Under what plan were the stock options to the CRBP officer granted?

The stock options were granted as an annual award under the issuer's 2024 Equity Compensation Plan, with a vesting schedule starting on January 14, 2027 and continuing monthly thereafter.